Indian Pediatrics, Journal Year: 2024, Volume and Issue: 61(10), P. 987 - 991
Published: Aug. 26, 2024
Language: Английский
World Neurosurgery, Journal Year: 2025, Volume and Issue: 194, P. 123579 - 123579
Published: Jan. 22, 2025
This study explores the integration of chimeric antigen receptor T-cell (CAR-T) therapy with convection enhanced delivery (CED) as a novel approach for treating diffuse intrinsic pontine glioma (DIPG), highly aggressive pediatric brain tumor limited treatment options. Preliminary clinical results indicate that CED improves CAR-T cell distribution within microenvironment, leading to promising anti-tumor responses. However, challenges such catheter-related complications and potential on-target/off-tumor toxicity remain. Ongoing research is essential optimize these strategies address ethical considerations surrounding patient safety equitable access innovative therapies. The aim assess safety, efficacy, cells delivered directly site via CED, thereby enhancing therapeutic outcomes while minimizing systemic side effects.
Language: Английский
Citations
0
STAR Protocols, Journal Year: 2025, Volume and Issue: 6(1), P. 103685 - 103685
Published: March 1, 2025
T cell-based therapies hold immense promise, but their production remains time-consuming and technically complex. Here, we present a protocol that streamlines the activation lentiviral transduction of primary human cells with artificial receptors. We describe steps for cell isolation, lentivirus production, simultaneous activation/transduction cells. By eliminating magnetic beads, sequential steps, lengthy spinoculation, this significantly enhances efficiency, scalability, accessibility research therapeutic applications.
Language: Английский
Citations
0
Cellular Oncology, Journal Year: 2025, Volume and Issue: unknown
Published: April 22, 2025
Chimeric antigen receptor (CAR) therapy has successfully treated relapsed/refractory hematological cancers. This strategy can effectively target tumor cells. However, despite positive outcomes in clinical applications, challenges remain to overcome. These hurdles pertain the production of drugs, solid resistance, and side effects related treatment. Some cases have been missed during drug preparation due manufacturing issues, prolonged times, high costs. mainly arise from vitro process, so reevaluating this process could minimize number patients. The immune cells are traditionally collected sent laboratory; after several steps, modified express CAR gene before being injected back into patient's body. During vivo method, is introduced inside allows for treatment begin sooner, avoiding potential failures associated In review, we will elaborate on using CAR, examine benefits approach, ultimately present available solutions incorporating practice.
Language: Английский
Citations
0
Rheumatology Science and Practice, Journal Year: 2024, Volume and Issue: 62(3), P. 262 - 279
Published: June 26, 2024
Autoimmunity is a pathological process associated with violation of immunological tolerance to normal structural components the body (autoantigens), predominance active (adaptive) immunity and manifested by hyperproduction autoantibodies. Systemic autoimmune rheumatic diseases (SARDs) are among most common severe nosological forms this pathology autoimmunity. Problems pharmacotherapy SARDs subject intensive research. At beginning 21st century, more than 20 biologic agents were developed for treatment rheumatoid arthritis – monoclonal antibodies (mAbs) recombinant proteins that control inflammation overproduction “pro-inflammatory” cytokines, use which has dramatically improved results pharmacotherapy. However, much less research been devoted studying possibilities aimed at selective suppression “autoimmune” component pathogenesis SADRs uncontrolled activation B cells restoration autoantigens. In spectrum drugs whose mechanism action cells, leading place occupied rituximab (RTM). It noteworthy years ago (2004), group researchers led prof. J.C. Edwards first demonstrated effectiveness RTM in patients RA, was soon successfully repositioned treat wide range SARDs. A major achievement CAR (сhimeric antigen receptor) T cell therapy, refractory hematological tumors. The main CART-cells genetically engineered T-cell receptor recognizes target without participation histocompatibility complex. Although limited, extremely impressive data regarding high remission rates have obtained adapting CD19 CART-cell therapy systemic lupus erythematosus (SLE) other standard immunosuppressive medications. article discusses SLE prospects further
Language: Английский
Citations
2
Indian Pediatrics, Journal Year: 2024, Volume and Issue: 61(10), P. 987 - 991
Published: Aug. 26, 2024
Language: Английский
Citations
0